Retatrutide is an investigational triple incretin receptor agonist with no current regulatory approval, while tesamorelin is a GHRH analogue licensed in the US for HIV-associated lipodystrophy but unlicensed in the UK
Source: New England Journal of Medicine - STEP 1 Trial 20% lower risk of heart attack and stroke SELECT trial showed semaglutide reduces major cardiovascular events (death, heart attack, stroke) by 20% in people with obesity
Diabetes 1995;44:11261131
Her response: Point people to her spa and a relatively new type of medication GLP-1 agonists, a class of drug thats become a weight loss phenomenon
Diet plays a key role in preventing it
[DOI] [PMC free article] [PubMed] [Google Scholar] 27.Serviddio G., Bellanti F., Stanca E., Lunetti P., Blonda M., Tamborra R., Siculella L., Vendemiale G., Capobianco L., Giudetti A.M